Current and potential treatments for cervical cancer

Current Cancer Drug Targets

Volumn 13, Issue 2, 2013, Pages 205-220

  Yee, Grace P C ^a   de Souza, Paul ^b   Khachigian, Levon M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Cervical cancer; Side effects; Targeted; Therapy

Indexed keywords

CAMPTOTHECIN; CAPECITABINE; CASPASE; CISPLATIN; CLUSTERIN; CYCLIN DEPENDENT KINASE 4; DOXORUBICIN; ETOPOSIDE; FLICE INHIBITORY PROTEIN; GEMCITABINE; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK TRANSCRIPTION FACTOR 1; IFOSFAMIDE; IRINOTECAN; MESSENGER RNA; METHOTREXATE; NAVELBINE; PACLITAXEL; PEGAPTANIB; PEMETREXED; PROTEIN BCL 2; SMALL INTERFERING RNA; STATHMIN; SURVIVIN; TOPOTECAN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; VINBLASTINE; WART VIRUS VACCINE; ZYC 101;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; CHEMORADIOTHERAPY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY (TOPIC); NONHUMAN; ONCOGENE C MYC; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; UTERINE CERVIX CANCER;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 84876851214     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313020009     Document Type: Review

References (170)

1. Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127 (12), 2893-2917.
2. Thun, M. J.; DeLancey, J. O.; Center, M. M.; Jemal, A.; Ward, E. M. The global burden of cancer: priorities for prevention. Carcinogenesis 2010, 31 (1), 100-110.
3. Stewart, B. W.; Kleihues P. (Eds) World Cancer Report. IARC Press Lyon 2003.
4. Walboomers, J. M. M.; Jacobs, M. V.; Manos, M. M.; Bosch, X.; Kummer, J. A.; Shah, K. V.; Snijders, P. J. F.; Peto, J.; Meijer, C. J.; Muñoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189 (1), 12-19.
5. Gien, L. T.; Beauchemin, M. C.; Thomas, G. Adenocarcinoma: a unique cervical cancer. Gynecol. Oncol. 2010, 116 (1), 140-146.
6. Movva, S.; Rodriguez, L.; Arias-Pulido, H.; Verschraegen, C. Novel chemotherapy approaches for cervical cancer. Cancer 2009, 115 (14), 3166-3180.
7. Ercoli, A.; Iannone, V.; Legge, F.; Fagotti, A.; Fanfani, F.; Carone, V.; D'Asta, M.; Scambia, G.; Ferrandina, G. Advances in surgical management of cervical cancer. Minerva. Ginecol. 2009, 61 (3), 227-237.
8. Keys, H. M.; Bundy, B. N.; Stehman, F. B.; Muderspach, L. I.; Chafe, W. E.; Suggs, C. L., 3rd; Walker, J. L.; Gersell, D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 1999, 340 (15), 1154-1161.
9. Rose, P. G.; Bundy, B. N.; Watkins, E. B.; Thigpen, J. T.; Deppe, G.; Maiman, M. A.; Clarke-Pearson, D. L.; Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999, 340 (15), 1144-1153.
10. Morris, M.; Eifel, P. J.; Lu, J.; Grigsby, P. W.; Levenback, C.; Stevens, R. E.; Rotman, M.; Gershenson, D. M.; Mutch, D. G. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 1999, 340 (15), 1137-1143.
11. Whitney, C. W.; Sause, W.; Bundy, B. N.; Malfetano, J. H.; Hannigan, E. V.; Fowler, W. C. Jr.; Clarke-Pearson, D. L.; Liao, S. Y. Randomised comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 1999, 17 (5), 1339-1348.
12. Peters, W. A. III; Liu, P.Y.; Barrett, R. J. II; Stock, R. J.; Monk, B. J.; Berek, J. S.; Souhami, L.; Grigsby, P.; Gordon, W. Jr.; Alberts, D. S. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2000, 18 (8), 1606-1613.
13. Tierney, J. F.; Vale, C.; Symonds, P. Concomitant and neoadjuvant chemotherapy for cervical cancer. Clin. Oncol. (R. Coll. Radiol.) 2008, 20 (6), 401-416.
14. Benedetti-Panici, P.; Greggi, S.; Scambia, G.; Amoroso, M.; Salerno, M. G.; Maneschi, F.; Cutillo, G.; Paratore, M. P.; Scorpiglione, N.; Mancuso, S. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur. J. Cancer 1998, 34 (3), 341-346.
15. Buda, A.; Fossati, R.; Colombo, N.; Fei, F.; Floriani, I.; Gueli Alletti, D.; Katsaros, D.; Landoni, F.; Lissoni, A.; Malzoni, C.; Sartori, E.; Scollo, P.; Torri, V.; Zola, P.; Mangioni, C. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J. Clin. Oncol. 2005, 23 (18), 4137-4145.
16. Basile, S.; Angioli, R.; Manci, N.; Palaia, I.; Plotti, F.; Benedetti Panici, P. Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting. Int. J. Gynecol. Cancer 2006, 16 (4), 1491-1497.
17. Legge, F.; Fuoco, G.; Lorusso, D.; Lucidi, A.; Borriello, M.; Pisconti, S.; Scambia, G.; Ferrandina, G. Pharmacotherapy of cervical cancer. Expert Opin. Pharmacother. 2010, 11 (12), 2059-2075.
18. Landoni, F.; Maneo, A.; Colombo, A.; Placa, F.; Milani, R.; Perego, P.; Favini, G.; Ferri, L.; Mangioni, C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350 (9077), 535-540.
19. Ferrandina, G.; Legge, F.; Fagotti, A.; Fanfani, F.; Distefano, M.; Morganti, A.; Cellini, N.; Scambia, G. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol. Oncol. 2007, 107 (1 Suppl 1), S127-132.
20. Thigpen, T.; Shingleton, H.; Homesley, H.; Lagasse, L.; Blessing, J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981, 48 (4), 899-903.
21. Tewari, K. S.; Monk, B. J. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin. Oncol. 2009, 36 (2), 170-180.
22. Moore, D. H.; Blessing, J. A.; McQuellon, R. P.; Thaler, H. T. Cella, D.; Benda, J.; Miller, D. S.; Olt, G.; King, S.; Boggess, J. F.; Rocereto, T. F. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2004, 22, 3113-3119.
23. Nagao, S.; Fujiwara, K.; Oda, T.; Ishikawa, H.; Koike, H.; Tanaka, H.; Kohno, I. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol. Oncol. 2005, 96 (3), 805-809.
24. Long, H. J. 3rd; Bundy, B. N.; Grendys, E. C., Jr.; Benda, J. A.; McMeekin, D. S.; Sorosky, J.; Miller, D. S.; Eaton, L. A.; Fiorica, J. V.; Gynecologic Oncology Group, Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2005, 23 (21), 4626-4633.
25. Bloss, J. D.; Blessing, J. A.; Behrens, B. C.; Mannel, R. S.; Rader, J. S.; Sood, A. K.; Markman, M.; Benda, J. Randomized Trial of Cisplatin and Ifosfamide With or Without Bleomycin in Squamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2002, 20 (7), 1832-1837.
26. Long, H. J. 3rd; Monk, B. J.; Huang, H. Q.; Grendys, E. C. Jr.; McMeekin, D. S.; Sorosky, J.; Miller, D. S.; Eaton, L. A.; Fiorica, J. V.; Gynecologic Oncology, G. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol. Oncol. 2006, 100 (3), 537-543.
27. Hildebrandt, B.; Wust, P.; Ahlers, O.; Dieing, A.; Sreenivasa, G.; Kerner, T.; Felix, R.; Riess, H. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 2002, 43 (1), 33-56.
28. van der Zee, J.; Gonzalez Gonzalez, D.; van Rhoon, G. C.; van Dijk, J. D.; van Putten, W. L.; Hart, A. A. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000, 355 (9210), 1119-1125.
29. Harima, Y.; Nagata, K.; Harima, K.; Ostapenko, V. V.; Tanaka, Y.; Sawada, S. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int. J. Hyperthermia 2001, 17 (2), 97-105.
30. Westermann, A. M.; Jones, E. L.; Schem, B. C.; van der Steen-Banasik, E. M.; Koper, P.; Mella, O.; Uitterhoeve, A. L.; de Wit, R.; van der Velden, J.; Burger, C.; van der Wilt, C. L.; Dahl, O.; Prosnitz, L. R.; van der Zee, J. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer 2005, 104 (4), 763-770.
31. Rose, P. G.; Degeest, K.; McMeekin, S.; Fusco, N. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 2007, 107 (2), 274-279.
32. Duenas-Gonzalez, A.; Zarba, J. J.; Patel, F.; Alcedo, J. C.; Beslija, S.; Casanova, L.; Pattaranutaporn, P.; Hameed, S.; Blair, J. M.; Barraclough, H.; Orlando, M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J. Clin. Oncol. 2011, 29 (13), 1678-1685.
33. Verma, A. K.; Arya, A. K.; Kumar, M.; Kumar, A.; Gupta, S.; Sharma, D.; Rath, G. Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study. J. Gynecol. Oncol. 2009, 20 (4), 221-226.
34. Hodge, L. S.; Downs, L. S. Jr.; Chura, J. C.; Thomas, S. G.; Callery, P. S.; Soisson, A. P.; Kramer, P.; Wolfe, S. S.; Tracy, T. S. Localized delivery of chemotherapy to the cervix for radiosensitization. Gynecol. Oncol. 2012, 127 (1), 121-125.
35. Su, J. H.; Wu, A.; Scotney, E.; Ma, B.; Monie, A.; Hung, C. F.; Wu, T. C. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs 2010, 24 (2), 109-129.
36. Sheets, E. E.; Urban, R. G.; Crum, C. P.; Hedley, M. L.; Politch, J. A.; Gold, M. A.; Muderspach, L. I.; Cole, G. A.; Crowley-Nowick, P. A. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol. 2003, 188 (4), 916-926.
37. Trimble, C. L.; Peng, S.; Kos, F.; Gravitt, P.; Viscidi, R.; Sugar, E.; Pardoll, D.; Wu, T. C. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin. Cancer Res. 2009, 15 (1), 361-367.
38. Tseng, C. W.; Trimble, C.; Zeng, Q.; Monie, A.; Alvarez, R. D.; Huh, W. K.; Hoory, T.; Wang, M. C.; Hung, C. F.; Wu, T. C. Lowdose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol. Immunother. 2009, 58 (5), 737-748.
39. Tseng, C. W.; Monie, A.; Trimble, C.; Alvarez, R. D.; Huh, W. K.; Buchsbaum, D. J.; Straughn, J. M., Jr.; Wang, M. C.; Yagita, H.; Hung, C. F.; Wu, T. C. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008, 26 (34), 4314-4319.
40. Hong, X.; Dong, T.; Hu, J.; Yi, T.; Li, W.; Zhang, Z.; Lin, S.; Niu, W. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int. J. Colorectal. Dis. 2012.
41. Finkelstein, S. E.; Rodriguez, F.; Dunn, M.; Farmello, M. J.; Smilee, R.; Janssen, W.; Kang, L.; Chuang, T.; Seigne, J.; Pow-Sang, J.; Torres-Roca, J. F.; Heysek, R.; Biagoli, M.; Shankar, R.; Scott, J.; Antonia, S.; Gabrilovich, D.; Fishman, M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy 2012, 4 (4), 373-382.
42. Ardavin, C.; Amigorena, S.; Reis e Sousa, C. Dendritic cells: immunobiology and cancer immunotherapy. Immunity 2004, 20 (1), 17-23.
43. Gilboa, E. DC-based cancer vaccines. J. Clin. Invest. 2007, 117 (5), 1195-1203.
44. Chung, J. K. Sodium iodide symporter: its role in nuclear medicine. J. Nucl. Med. 2002, 43 (9), 1188-1200.
45. Spitzweg, C.; Dietz, A. B.; O'Connor, M. K.; Bergert, E. R.; Tindall, D. J.; Young, C. Y.; Morris, J. C. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001, 8 (20), 1524-1531.
46. Kang, J. H.; Chung, J. K.; Lee, Y. J.; Shin, J. H.; Jeong, J. M.; Lee, D. S.; Lee, M. C. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J. Nucl. Med. 2004, 45 (9), 1571-1576.
47. Jeon, Y. H.; Lee, H. W.; Lee, Y. L.; Kim, J. E.; Hwang, M. H.; Jeong, S. Y.; Lee, S. W.; Ahn, B. C.; Ha, J. H.; Lee, J. Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer. Cancer Biother. Radiopharm. 2011, 26 (6), 671-679.
48. Zeng, Q.; Peng, S.; Monie, A.; Yang, M.; Pang, X.; Hung, C. F.; Wu, T. C. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum. Gene Ther. 2011, 22 (7), 809-819.
49. Baguley, B. C. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003, 4 (3), 141-148.
50. Cai, S. X. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat. Anticancer Drug Discov. 2007, 2 (1), 79-101.
51. Moser, H. E.; Dervan, P. B. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 1987, 238 (4827), 645-650.
52. Hacia, J. G.; Dervan, P. B.; Wold, B. J., Inhibition of Klenow fragment DNA polymerase on double-helical templates by oligonucleotide-directed triple-helix formation. Biochemistry 1994, 33 (20), 6192-6200.
53. Vasquez, K. M.; Wensel, T. G.; Hogan, M. E.; Wilson, J. H. Highefficiency triple-helix-mediated photo-cross-linking at a targeted site within a selectable mammalian gene. Biochemistry 1996, 35 (33), 10712-10719.
54. Helm, C. W.; Shrestha, K.; Thomas, S.; Shingleton, H. M.; Miller, D. M. A unique c-myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro. Gynecol. Oncol. 1993, 49 (3), 339-343.
55. Keller, W.; Crouch, R. Degradation of DNA RNA hybrids by ribonuclease H and DNA polymerases of cellular and viral origin. Proc. Natl. Acad. Sci. U.S. A 1972, 69 (11), 3360-3364.
56. Yatabe, N.; Kyo, S.; Kondo, S.; Kanaya, T.; Wang, Z.; Maida, Y.; Takakura, M.; Nakamura, M.; Tanaka, M.; Inoue, M. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther. 2002, 9 (7), 624-630.
57. Sima, N.; Wang, S.; Wang, W.; Kong, D.; Xu, Q.; Tian, X.; Luo, A.; Zhou, J.; Xu, G.; Meng, L.; Lu, Y.; Ma, D. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol. Oncol. 2007, 106 (2), 299-304.
58. Nakamura, K.; Hongo, A.; Kodama, J.; Miyagi, Y.; Yoshinouchi, M.; Kudo, T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res. 2000, 60 (3), 760-765.
59. Marquez-Gutierrez, M. A.; Benitez-Hess, M. L.; DiPaolo, J. A.; Alvarez-Salas, L. M. Effect of combined antisense oligodeoxynucleotides directed against the human papillomavirus type 16 on cervical carcinoma cells. Arch. Med. Res. 2007, 38 (7), 730-738.
60. Cho, C. W.; Poo, H.; Cho, Y. S.; Cho, M. C.; Lee, K. A.; Lee, S. J.; Park, S. N.; Kim, I. K.; Jung, Y. K.; Choe, Y. K.; Yeom, Y. I.; Choe, I. S.; Yoon, D. Y. HPV E6 antisense induces apoptosis in CaSki cells via suppression of E6 splicing. Exp. Mol. Med. 2002, 34 (2), 159-166.
61. Yamayoshi, A.; Kato, K.; Iwase, R.; Yamaoka, T.; Wake, N.; Murakami, A. Photodynamic antisense therapy: regulation of cervical carcinoma cells by psoralen-conjugated oligonucleotides. Nucleic Acids Res. Suppl. 2003 (3), 75-76.
62. Choo, C. K.; Ling, M. T.; Suen, C. K.; Chan, K. W.; Kwong, Y. L. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol. Oncol. 2000, 78 (3 Pt 1), 293-301.
63. Wu, S.; Meng, L.; Wang, S.; Wang, W.; Xi, L.; Tian, X.; Chen, G.; Wu, Y.; Zhou, J.; Xu, G.; Lu, Y.; Ma, D. Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA. Clin. Cancer Res. 2006, 12 (7 Pt 1), 2032-2037.
64. Puerta-Fernandez, E.; Romero-Lopez, C.; Barroso-delJesus, A.; Berzal-Herranz, A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol. Rev. 2003, 27 (1), 75-97.
65. DiPaolo, J. A.; Alvarez-Salas, L. M. Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin. Biol. Ther. 2004, 4 (8), 1251-1264.
66. Kore, A. R.; Vaish, N. K.; Kutzke, U.; Eckstein, F. Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Res. 1998, 26 (18), 4116-4120.
67. DeYoung, M.; Siwkowski, A. M.; Lian, Y.; Hampel, A. Catalytic properties of hairpin ribozymes derived from Chicory yellow mottle virus and arabis mosaic virus satellite RNAs. Biochemistry 1995, 34 (48), 15785-15791.
68. Zheng, Y.; Zhang, J.; Rao, Z. Ribozyme targeting HPV16 E6E7 transcripts in cervical cancer cells suppresses cell growth and sensitizes cells to chemotherapy and radiotherapy. Cancer Biol. Ther. 2004, 3 (11), 1129-1134; discussion 1135-1136.
69. Liu, H.; Guo, S.; Roll, R.; Li, J.; Diao, Z.; Shao, N.; Riley, M. R.; Cole, A. M.; Robinson, J. P.; Snead, N. M.; Shen, G.; Guo, P. Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol. Ther. 2007, 6 (5), 697-704.
70. Santoro, S. W.; Joyce, G. F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U.S. A 1997, 94 (9), 4262-4266.
71. Silverman, S. K. In vitro selection, characterization, and application of deoxyribozymes that cleave RNA. Nucleic Acids Res. 2005, 33 (19), 6151-6163.
72. Dass, C. R.; Saravolac, E. G.; Li, Y.; Sun, L. Q. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 2002, 12 (5), 289-299.
73. Lu, Z. X.; Ye, M.; Yan, G. R.; Li, Q.; Tang, M.; Lee, L. M.; Sun, L. Q.; Cao, Y. Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther. 2005, 12 (7), 647-654.
74. Wahlestedt, C.; Salmi, P.; Good, L.; Kela, J.; Johnsson, T.; Hokfelt, T.; Broberger, C.; Porreca, F.; Lai, J.; Ren, K.; Ossipov, M.; Koshkin, A.; Jakobsen, N.; Skouv, J.; Oerum, H.; Jacobsen, M. H.; Wengel, J. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (10), 5633-5638.
75. Guvakova, M. A.; Yakubov, L. A.; Vlodavsky, I.; Tonkinson, J. L.; Stein, C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 1995, 270 (6), 2620-2627.
76. Rockwell, P.; O'Connor, W. J.; King, K.; Goldstein, N. I.; Zhang, L. M.; Stein, C. A. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (12), 6523-6528.
77. Koshkin, A. A.; Wengel, J. Synthesis of Novel 2',3'-Linked Bicyclic Thymine Ribonucleosides. J. Org. Chem. 1998, 63 (8), 2778-2781.
78. Braasch, D. A.; Corey, D. R. Locked nucleic acid (LNA): finetuning the recognition of DNA and RNA. Chem. Biol. 2001, 8 (1), 1-7.
79. Kumar, R.; Singh, S. K.; Koshkin, A. A.; Rajwanshi, V. K.; Meldgaard, M.; Wengel, J. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA. Bioorg. Med. Chem. Lett. 1998, 8 (16), 2219-2222.
80. Fahmy, R. G.; Khachigian, L. M. Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. Nucleic Acids Res. 2004, 32 (7), 2281-2285.
81. Fluiter, K.; Frieden, M.; Vreijling, J.; Koch, T.; Baas, F. Evaluation of LNA-modified DNAzymes targeting a single nucleotide polymorphism in the large subunit of RNA polymerase II. Oligonucleotides 2005, 15 (4), 246-254.
82. Reyes-Gutierrez, P.; Alvarez-Salas, L. M. Cleavage of HPV-16 E6/E7 mRNA mediated by modified 10-23 deoxyribozymes. Oligonucleotides 2009, 19 (3), 233-242.
83. Benítez-Hess, M. L.; Reyes-Gutiérrez, P.; Alvarez-Salas, L. M. Inhibition of Human Papillomavirus Expression Using DNAzymes. J. Goodchild (ed.), Therapeutic Oligonucleotides, Methods Mol. Biol. 2011, 764, 317-335.
84. Nykanen, A.; Haley, B.; Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001, 107 (3), 309-321.
85. Meister, G.; Landthaler, M.; Dorsett, Y.; Tuschl, T. Sequencespecific inhibition of microRNA-and siRNA-induced RNA silencing. RNA 2004, 10 (3), 544-550.
86. Bernstein, E.; Caudy, A. A.; Hammond, S. M.; Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409 (6818), 363-366.
87. Koivusalo, R.; Mialon, A.; Pitkanen, H.; Westermarck, J.; Hietanen, S. Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists. Cancer Res. 2006, 66 (24), 11817-11824.
88. Wang, Z.; Rao, D. D.; Senzer, N.; Nemunaitis, J. RNA interference and cancer therapy. Pharm. Res. 2011, 28 (12), 2983-2995.
89. Qi, Z.; Xu, X.; Zhang, B.; Li, Y.; Liu, J.; Chen, S.; Chen, G.; Huo, X. Effect of simultaneous silencing of HPV-18 E6 and E7 on inducing apoptosis in HeLa cells. Biochem. Cell Biol. 2010, 88 (4), 697-704.
90. Yamato, K.; Fen, J.; Kobuchi, H.; Nasu, Y.; Yamada, T.; Nishihara, T.; Ikeda, Y.; Kizaki, M.; Yoshinouchi, M. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther. 2006, 13 (3), 234-241.
91. Hong, D.; Lu, W.; Ye, F.; Hu, Y.; Xie, X. Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells. Br. J. Cancer 2009, 101 (10), 1798-1804.
92. Zhou, J.; Peng, C.; Li, B.; Wang, F.; Zhou, C.; Hong, D.; Ye, F.; Cheng, X.; Lu, W.; Xie, X. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol. Oncol. 2012, 124 (2), 296-302.
93. Chang, J. T.; Kuo, T. F.; Chen, Y. J.; Chiu, C. C.; Lu, Y. C.; Li, H. F.; Shen, C. R.; Cheng, A. J. Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers. Cancer Gene Ther. 2010, 17 (12), 827-836.
94. Lea, J. S.; Sunaga, N.; Sato, M.; Kalahasti, G.; Miller, D. S.; Minna, J. D.; Muller, C. Y. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. Reprod. Sci. 2007, 14 (1), 20-28.
95. Tan, S.; Hougardy, B. M.; Meersma, G. J.; Schaap, B.; de Vries, E. G.; van der Zee, A. G.; de Jong, S. Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells. Mol. Pharmacol. 2012, 81 (5), 701-709.
96. Yamato, K.; Yamada, T.; Kizaki, M.; Ui-Tei, K.; Natori, Y.; Fujino, M.; Nishihara, T.; Ikeda, Y.; Nasu, Y.; Saigo, K.; Yoshinouchi, M. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther. 2008, 15 (3), 140-153.
97. Gu, W.; Payne, E.; Sun, S.; Burgess, M.; McMillan, N. A. Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene Ther. 2011, 18 (3), 219-227.
98. Gu, W.; Yeo, E.; McMillan, N.; Yu, C. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther. 2011, 18 (12), 897-905.
99. Liu, W. L.; Green, N.; Seymour, L. W.; Stevenson, M. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. Cancer Gene Ther. 2009, 16 (10), 764-775.
100. Putral, L. N.; Bywater, M. J.; Gu, W.; Saunders, N. A.; Gabrielli, B. G.; Leggatt, G. R.; McMillan, N. A. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol. Pharmacol. 2005, 68 (5), 1311-1319.
101. Jung, H. S.; Erkin, O. C.; Kwon, M. J.; Kim, S. H.; Jung, J. I.; Oh, Y. K.; Her, S. W.; Ju, W.; Choi, Y. L.; Song, S. Y.; Kim, J. K.; Kim, Y. D.; Shim, G. Y.; Shin, Y. K. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int. J. Cancer 2012, 130 (8), 1925-1936.
102. Steinberg, J.; Oyasu, R.; Lang, S.; Sintich, S.; Rademaker, A.; Lee, C.; Kozlowski, J. M.; Sensibar, J. A. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 1997, 3 (10), 1707-1711.
103. Redondo, M.; Villar, E.; Torres-Munoz, J.; Tellez, T.; Morell, M.; Petito, C. K. Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 2000, 157 (2), 393-399.
104. Miyake, H.; Gleave, M. E.; Arakawa, S.; Kamidono, S.; Hara, I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. Gynecol. Oncol. 2006, 103, 996-1000.
105. Park, D. C.; Yeo, S. G.; Shin, E. Y.; Mok, S. C.; Kim, D. H. Clusterin confers paclitaxel resistance in cervical cancer. Gynecol. Oncol. 2006, 103 (3), 996-1000.
106. Wang, X.; Yu, B.; Wu, Y.; Lee, R. J.; Lee, L. J. Efficient downregulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery. Anticancer. Res. 2011, 31 (5), 1619-1626.
107. Moinova, H. R.; Chen, W. D.; Shen, L.; Smiraglia, D.; Olechnowicz, J.; Ravi, L.; Kasturi, L.; Myeroff, L.; Plass, C.; Parsons, R.; Minna, J.; Willson, J. K.; Green, S. B.; Issa, J. P.; Markowitz, S. D. HLTF gene silencing in human colon cancer. Proc. Natl. Acad. Sci U.S.A. 2002, 99 (7), 4562-4567.
108. Hibi, K.; Nakayama, H.; Kanyama, Y.; Kodera, Y.; Ito, K.; Akiyama, S.; Nakao, A. Methylation pattern of hltf gene in digestive tract cancers. Int. J. Cancer 2003, 104 (4), 433-436.
109. Debauve, G.; Nonclercq, D.; Ribaucour, F.; Wiedig, M.; Gerbaux, C.; Leo, O.; Laurent, G.; Journe, F.; Belayew, A.; Toubeau, G. Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis. Mol. Cancer 2006, 5, 23.
110. Cho, S.; Cinghu, S.; Yu, J. R.; Park, W. Y. Helicase-like transcription factor confers radiation resistance in cervical cancer through enhancing the DNA damage repair capacity. J. Cancer Res. Clin. Oncol. 2011, 137 (4), 629-637.
111. Kubota, H.; Suzuki, T.; Lu, J.; Takahashi, S. Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines. Int. J. Radiat. Biol. 2005, 81 (9), 701-709.
112. Tsuruma, T.; Iwayama, Y.; Ohmura, T.; Katsuramaki, T.; Hata, F.; Furuhata, T.; Yamaguchi, K.; Kimura, Y.; Torigoe, T.; Toyota, N.; Yagihashi, A.; Hirohashi, Y.; Asanuma, H.; Shimozawa, K.; Okazaki, M.; Mizushima, Y.; Nomura, N.; Sato, N.; Hirata, K. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 2008, 6, 24.
113. Suzuki, J.; Ogawa, M.; Takayama, K.; Taniyama, Y.; Morishita, R.; Hirata, Y.; Nagai, R.; Isobe, M. Ultrasound-microbubblemediated intercellular adhesion molecule-1 small interfering ribonucleic acid transfection attenuates neointimal formation after arterial injury in mice. J. Am. Coll. Cardiol. 2010, 55 (9), 904-913.
114. Figueiredo, M.; Esenaliev, R. PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors. J. Drug Deliv. 2012, 2012, 767839.
115. Newman, C. M.; Bettinger, T. Gene therapy progress and prospects: ultrasound for gene transfer. Gene Ther. 2007, 14 (6), 465-475.
116. Chen, Z. Y.; Liang, K.; Xie, M. X.; Wang, X. F.; Lu, Q.; Zhang, J. Induced apoptosis with ultrasound-mediated microbubble destruction and shRNA targeting survivin in transplanted tumors. Adv. Ther. 2009, 26 (1), 99-106.
117. Song, H.; Xin, X. Y.; Xiao, F.; Wang, D. T.; Yue, Q. H.; Han, X. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 136 (1), 83-89.
118. Li, Q. X.; Zhao, J.; Liu, J. Y.; Jia, L. T.; Huang, H. Y.; Xu, Y. M.; Zhang, Y.; Zhang, R.; Wang, C. J.; Yao, L. B.; Chen, S. Y.; Yang, A. G. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol. Ther. 2006, 5 (7), 860-866.
119. Li, Y.; Li, H.; Yao, G.; Li, W.; Wang, F.; Jiang, Z.; Li, M. Inhibition of telomerase RNA (hTR) in cervical cancer by adenovirus-delivered siRNA. Cancer Gene Ther. 2007, 14 (8), 748-755.
120. Ryang, D. Y.; Joo, Y. E.; Chung, K. M.; Lim, S. R.; Jeong, H. K.; Kim, H. I.; Lee, W. S.; Park, C. H.; Kim, H. S.; Choi, S. K.; Rew, J. S.; Lee, J. H.; Park, C. S. Expression of c-FLIP in gastric cancer and its relation to tumor cell proliferation and apoptosis. Korean J. Intern. Med. 2007, 22 (4), 263-269.
121. Hou, X. J.; Zhang, Y. Z.; Liu, X.; Meng, L. H.; Qiao, Y. B. Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. J. Exp. Clin. Cancer Res. 2009, 28, 70.
122. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J. L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L. E.; Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388 (6638), 190-195.
123. Luo, A.; Wang, W.; Sima, N.; Lu, Y.; Zhou, J.; Xu, G.; Yu, H.; Wang, S.; Ma, D. Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy. Cancer Lett. 2008, 271 (2), 323-332.
124. Wang, X.; Ren, J.; Lin, F.; Wei, J.; Long, M.; Yan, L.; Zhang, H. Z. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biology & Therapy 2010, 10 (6), 632-643.
125. Soignet, S. L.; Frankel, S. R.; Douer, D.; Tallman, M. S.; Kantarjian, H.; Calleja, E.; Stone, R. M.; Kalaycio, M.; Scheinberg, D. A.; Steinherz, P.; Sievers, E. L.; Coutre, S.; Dahlberg, S.; Ellison, R.; Warrell, R. P., Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 2001, 19 (18), 3852-3860.
126. Evens, A. M.; Tallman, M. S.; Gartenhaus, R. B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk. Res. 2004, 28 (9), 891-900.
127. Androic, I.; Kramer, A.; Yan, R.; Rodel, F.; Gatje, R.; Kaufmann, M.; Strebhardt, K.; Yuan, J. Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008, 8, 391.
128. Rossi, A.; Ciafre, S.; Balsamo, M.; Pierimarchi, P.; Santoro, M. G. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res. 2006, 66 (15), 7678-7685.
129. Dass, C. R.; Khachigian, L. M.; Choong, P. F. c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Mol. Cancer Res. 2008, 6 (8), 1289-1292.
130. Zhang, Y.; Pu, X.; Shi, M.; Chen, L.; Song, Y.; Qian, L.; Yuan, G.; Zhang, H.; Yu, M.; Hu, M.; Shen, B.; Guo, N. Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 2007, 7, 145.
131. Cai, H.; Santiago, F. S.; Prado-Lourenco, L.; Wang, B.; Patrikakis, M.; Davenport, M. P.; Maghzal, G. J.; Stocker, R.; Parish, C. R.; Chong, B. H.; Lieschke, G. J.; Wong, T. W.; Chesterman, C. N.; Francis, D. J.; Moloney, F. J.; Barnetson, R. S.; Halliday, G. M.; Khachigian, L. M. DNAzyme Targeting c-jun Suppresses Skin Cancer Growth. Sci. Transl. Med. 2012, 4 (139), 139ra82.
132. Maritz, M. F.; van der Watt, P. J.; Holderness, N.; Birrer, M. J.; Leaner, V. D. Inhibition of AP-1 suppresses cervical cancer cell proliferation and is associated with p21 expression. Biol. Chem. 2011, 392 (5), 439-448.
133. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.; Rohl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H. P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432 (7014), 173-178.
134. Kim, D. H.; Longo, M.; Han, Y.; Lundberg, P.; Cantin, E.; Rossi, J. J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 2004, 22 (3), 321-325.
135. Wu, S. Y.; Singhania, A.; Burgess, M.; Putral, L. N.; Kirkpatrick, C.; Davies, N. M.; McMillan, N. A. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Ther. 2011, 18 (1), 14-22.
136. Dutta, T.; Burgess, M.; McMillan, N. A.; Parekh, H. S. Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine 2010, 6 (3), 463-470.
137. Gu, W.; Putral, L.; Hengst, K.; Minto, K.; Saunders, N. A.; Leggatt, G.; McMillan, N. A. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther. 2006, 13 (11), 1023-1032.
138. Kuroda, M.; Kiyono, T.; Oikawa, K.; Yoshida, K.; Mukai, K. The human papillomavirus E6 and E7 inducible oncogene, hWAPL, exhibits potential as a therapeutic target. Br. J. Cancer 2005, 92 (2), 290-293.
139. Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Therapy 2005, 12, 461-466.
140. Chen, Z.; Liang, K.; Xie, M.; Wang, X.; Lu, Q.; Zhang, J. Novel ultrasound-targeted microbubble destruction mediated short hairpin RNA plasmid transfection targeting survivin inhibits gene expression and induces apoptosis of HeLa cells. Mol. Biol. Rep. 2009, 36 (8), 2059-2067.
141. Stoltenburg, R.; Reinemann, C.; Strehlitz, B. SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 2007, 24 (4), 381-403.
142. Ellington, A. D.; Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818.
143. Gragoudas, E. S.; Adamis, A. P.; Cunningham, E. T., Jr.; Feinsod, M.; Guyer, D. R.; Group, V. I. S. i. O. N. C. T. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351 (27), 2805-2816.
144. Toscano-Garibay, J. D.; Benitez-Hess, M. L.; Alvarez-Salas, L. M. Isolation and characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch. Med. Res. 2011, 42 (2), 88-96.
145. Eaton, S.; Wiktor, P.; Thirstrup, D.; Lake, D.; Nagaraj, V. J. Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes. Biochem. Biophys. Res. Commun. 2011, 405 (1), 1-6.
146. Maduro, J. H.; de Vries, E. G.; Meersma, G. J.; Hougardy, B. M.; van der Zee, A. G.; de Jong, S. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72 (2), 543-552.
147. Horinaka, M.; Yoshida, T.; Shiraishi, T.; Nakata, S.; Wakada, M.; Nakanishi, R.; Nishino, H.; Sakai, T. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem. Biophys. Res. Commun. 2005, 333 (3), 833-838.
148. Noguera, R.; Fredlund, E.; Piqueras, M.; Pietras, A.; Beckman, S.; Navarro, S.; Pahlman, S. HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization. Clin. Cancer Res. 2009, 15 (23), 7130-7136.
149. Grothey, A.; Galanis, E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat. Rev. Clin. Oncol. 2009, 6 (9), 507-518.
150. Monk, B. J.; Sill, M. W.; Burger, R. A.; Gray, H. J.; Buekers, T. E.; Roman, L. D. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. 2009, 27 (7), 1069-1074.
151. Shen, L.; Shui, Y.; Wang, X.; Sheng, L.; Yang, Z.; Xue, D.; Wei, Q. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer 2008, 8, 232.
152. Noordhuis, M. G.; Eijsink, J. J.; Ten Hoor, K. A.; Roossink, F.; Hollema, H.; Arts, H. J.; Pras, E.; Maduro, J. H.; Reyners, A. K.; de Bock, G. H.; Wisman, G. B.; Schuuring, E.; van der Zee, A. G. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin. Cancer Res. 2009, 15 (23), 7389-7397.
153. Santin, A. D.; Sill, M. W.; McMeekin, D. S.; Leitao, M. M., Jr.; Brown, J.; Sutton, G. P.; Van Le, L.; Griffin, P.; Boardman, C. H. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 2011, 122 (3), 495-500.
154. Schilder, R. J.; Sill, M. W.; Lee, Y. C.; Mannel, R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int. J. Gynecol. Cancer 2009, 19 (5), 929-933.
155. Farley, J.; Sill, M. W.; Birrer, M.; Walker, J.; Schilder, R. J.; Thigpen, J. T.; Coleman, R. L.; Miller, B. E.; Rose, P. G.; Lankes, H. A. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol. Oncol. 2011, 121 (2), 303-308.
156. Monk, B. J.; Willmott, L. J.; Sumner, D. A. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol. Oncol. 2010, 116, 181-186.
157. Basu, A.; Krishnamurthy, S. Cellular responses to cisplatin-induced DNA damage. J. Nucleic Acids 2010, 2010, 1-16.
158. Liu, Y.; Xing, H.; Han, X. Mechanism of cisplatin-induced apoptosis in HeLa cells. Chinese J. Clin. Oncol. 2005, 2 (6) 866-869.
159. Muscolini, M.; Cianfrocca, R.; Sajeva, A.; Mozzetti, S.; Ferrandina, G.; Costanzo, A.; Tuosto, L. Trichostatin A upregulates p73 and induces Bax-dependent apoptosis in cisplatinresistant ovarian cancer cells. Mol. Cancer Ther. 2008, 7 (6), 1410-1419.
160. Chaney, S. G.; Campbell, S. L.; Bassett, E.; Wu, Y. Recognition and processing of cisplatin-and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 2005, 53 (1), 3-11.
161. Brozovic, A.; Fritz, G.; Christmann, M. Long-term activation of SAPK/JNK, p38 kinase and Fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int. J. Cancer 2004, 112, 974-985.
162. Ishibashi, T.; Lippard, S. J. Telomere loss in cells treated with cisplatin. Proc. Natl. Acad. Sci. U.S. A 1998, 95 (8), 4219-4223.
163. Wang, D.; Lippard, S. J. Cisplatin-induced post-translational modification of histones H3 and H4. J. Biol. Chem. 2004, 279 (20), 20622-20625.
164. Xie, S. Y.; Li, Y. J.; Wang, P. Y.; Jiao, F.; Zhang, S.; Zhang, W. J. miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells. Oncol. Rep. 2010, 23 (6), 1693-700.
165. Splettstoesser, F.; Florea, A.-M.; Büsselberg, D. IP3 receptor antagonist, 2-APB, attenuates cisplatin induced Ca2t-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis. Br. J. Pharmacol. 2007, 151, 1176-1186.
166. Jordon, M. A.; Toso, R. J.; Thrower, D.; Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9552-9556.
167. Ding, A. H.; Porteu, F.; Sanchez, E.; Nathan, C. F. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990, 248 (4953), 370-372.
168. Kirikae, T.; Ojima, I.; Kirikae, F.; Ma, Z.; Kuduk, S. D.; Slater, J. C.; Takeuchi, C. S.; Bounaud, P. Y.; Nakano, M. Structural requirements of taxoids for nitric oxide and tumor necrosis factor production by murine macrophages. Biochem. Biophys. Res. Commun. 1996, 227 (1), 227-235.
169. Cassidy, P. B.; Moos, P. J.; Kelly, R. C.; Fitzpatrick, F. A. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin. Cancer Res. 2002, 8 (3), 846-855.
170. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260 (27), 14873-14878.